The multicenter phase II TBCRC026 study investigated the correlation between early metabolic changes on 18F-FDG-PET/CT and pCR in patients with stage II-III estrogen receptor (ER)-negative, HER2-positive breast cancer, receiving neoadjuvant HP without chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.